Nevertheless, the Spiranza—an ASO drug that was developed for SMA patients—blocks splicing silencers near the exon 7 of the SMN2 gene thus generating properly spliced (exon 7 included) transcripts that encode functional SMN protein. Here, SMN1 is linked to proximal spinal muscular atrophy.